Switch theme
Sign up to access all valuation multiples
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
2011
32
LTM Revenue $2.6M
LTM EBITDA -$30.6M
$45.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Clearside Biomedical has a last 12-month revenue (LTM) of $2.6M and a last 12-month EBITDA of -$30.6M.
In the most recent fiscal year, Clearside Biomedical achieved revenue of $1.7M and an EBITDA of -$24.3M.
Clearside Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Clearside Biomedical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.6M | XXX | $1.7M | XXX | XXX | XXX |
| Gross Profit | $2.5M | XXX | $1.5M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | -$30.6M | XXX | -$24.3M | XXX | XXX | XXX |
| EBITDA Margin | -1168% | XXX | -1463% | XXX | XXX | XXX |
| EBIT | -$28.3M | XXX | -$28.9M | XXX | XXX | XXX |
| EBIT Margin | -1080% | XXX | -1736% | XXX | XXX | XXX |
| Net Profit | -$35.2M | XXX | -$34.4M | XXX | XXX | XXX |
| Net Margin | -1346% | XXX | -2064% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Clearside Biomedical's stock price is $1.
Clearside Biomedical has current market cap of $58.3M, and EV of $45.3M.
See Clearside Biomedical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45.3M | $58.3M | XXX | XXX | XXX | XXX | $-0.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Clearside Biomedical has market cap of $58.3M and EV of $45.3M.
Clearside Biomedical's trades at 27.2x EV/Revenue multiple, and -1.9x EV/EBITDA.
Equity research analysts estimate Clearside Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Clearside Biomedical has a P/E ratio of -1.7x.
See valuation multiples for Clearside Biomedical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $58.3M | XXX | $58.3M | XXX | XXX | XXX |
| EV (current) | $45.3M | XXX | $45.3M | XXX | XXX | XXX |
| EV/Revenue | 17.3x | XXX | 27.2x | XXX | XXX | XXX |
| EV/EBITDA | -1.5x | XXX | -1.9x | XXX | XXX | XXX |
| EV/EBIT | -1.6x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | 18.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | -1.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialClearside Biomedical's last 12 month revenue growth is 43%
Clearside Biomedical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Clearside Biomedical's rule of 40 is -237% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Clearside Biomedical's rule of X is -1060% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Clearside Biomedical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 43% | XXX | 44% | XXX | XXX | XXX |
| EBITDA Margin | -1168% | XXX | -1463% | XXX | XXX | XXX |
| EBITDA Growth | 73% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -237% | XXX | -1420% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1060% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1117% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1827% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Clearside Biomedical acquired XXX companies to date.
Last acquisition by Clearside Biomedical was XXXXXXXX, XXXXX XXXXX XXXXXX . Clearside Biomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Clearside Biomedical founded? | Clearside Biomedical was founded in 2011. |
| Where is Clearside Biomedical headquartered? | Clearside Biomedical is headquartered in United States of America. |
| How many employees does Clearside Biomedical have? | As of today, Clearside Biomedical has 32 employees. |
| Who is the CEO of Clearside Biomedical? | Clearside Biomedical's CEO is Dr. George Lasezkay, J.D.,Pharm.D.. |
| Is Clearside Biomedical publicy listed? | Yes, Clearside Biomedical is a public company listed on NAS. |
| What is the stock symbol of Clearside Biomedical? | Clearside Biomedical trades under CLSD ticker. |
| When did Clearside Biomedical go public? | Clearside Biomedical went public in 2016. |
| Who are competitors of Clearside Biomedical? | Similar companies to Clearside Biomedical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Clearside Biomedical? | Clearside Biomedical's current market cap is $58.3M |
| What is the current revenue of Clearside Biomedical? | Clearside Biomedical's last 12 months revenue is $2.6M. |
| What is the current revenue growth of Clearside Biomedical? | Clearside Biomedical revenue growth (NTM/LTM) is 43%. |
| What is the current EV/Revenue multiple of Clearside Biomedical? | Current revenue multiple of Clearside Biomedical is 17.3x. |
| Is Clearside Biomedical profitable? | Yes, Clearside Biomedical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Clearside Biomedical? | Clearside Biomedical's last 12 months EBITDA is -$30.6M. |
| What is Clearside Biomedical's EBITDA margin? | Clearside Biomedical's last 12 months EBITDA margin is -1168%. |
| What is the current EV/EBITDA multiple of Clearside Biomedical? | Current EBITDA multiple of Clearside Biomedical is -1.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
